Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China.
Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday.
Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday.
3SBio's shares fell 6.41 per cent to HK$28.45 on Friday.
The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
9 minutes ago
- RTHK
McDonald's reportedly to sell 8 Hong Kong properties
McDonald's reportedly to sell 8 Hong Kong properties McDonald's is said to be planning to sell eight prime retail properties in the SAR, with the largest on Salisbury Road in Tsim Sha Tsui. Photo: RTHK Fast food giant McDonald's is planning to sell eight prime retail properties in Hong Kong with a total market value of HK$1.2 billion, according to property firm JLL. In a statement on Monday, JLL said it has been appointed as the sole agent for the sales, which will be conducted via public tender on September 16. The agency said the properties are in Tsim Sha Tsui, Causeway Bay, Mong Kok, Kennedy Town, Tai Kok Tsui, Yuen Long, Tsuen Wan and Tsz Wan Shan, and range from 6,800 to 19,000 square feet in size. The largest is the ground floor and basement of Star House on Salisbury Road in Tsim Sha Tsui. The company said the properties are all secured with long-term McDonald's leases and will be available for purchase either individually or as a portfolio. Eunice Tang, executive director of capital markets at JLL in Hong Kong, said the sites will be supported by high rental yields with a full occupancy rate. "Most of these McDonald's restaurants have been iconic dining destinations for over 30 years, with some operating 24/7, which underscores the strength and resilience of the tenants' businesses," she said. Tang said there are no changes planned to the chain's restaurants in those locations and they remain operational.
South China Morning Post
an hour ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
HKFP
an hour ago
- HKFP
CK Hutchison eyes inviting Chinese ‘major strategic investor' to Panama ports deal
Hong Kong conglomerate CK Hutchison said Monday it was eyeing inviting a Chinese 'major strategic investor' to join a US-led consortium negotiating the sale of its global ports business outside China, including operations at the Panama Canal. The firm said in March it was offloading the firms — including operations in the vital Central American waterway — to a group led by asset manager BlackRock for US$19 billion in cash. The sale was seen as a political victory for US President Donald Trump, who had vowed to 'take back' the Panama Canal from alleged Chinese control, prompting Beijing's ire. China's market regulator said in March it was reviewing the deal. '(CK Hutchison) remains in discussions with members of the consortium with a view to inviting (a) major strategic investor from (China) to join as a significant member of the consortium,' the group said in a stock exchange filing. The firm added that changes to the consortium's membership and deal structure will be needed for the deal 'to be capable of being approved by all relevant authorities'. CK Hutchison announced in March it was offloading its global ports business outside China — including operations in the vital Central American waterway — to a group led by asset manager BlackRock for $19 billion in cash. The sale was seen as a political victory for US President Donald Trump, who had vowed to 'take back' the Panama Canal from alleged Chinese control, drawing Beijing's ire. China's market regulator said in March it was reviewing the deal. CK Hutchison said Monday that the 'period for exclusive negotiations' mentioned in the March announcement had expired, but that discussions will continue. It did not name the major Chinese investor. China's biggest shipping company Cosco was set to join the consortium and was requesting veto rights or equivalent powers, Bloomberg News reported. Bloomberg Intelligence analyst Denise Wong told the outlet that 'ongoing negotiations and the reported inclusion of Cosco Shipping in the consortium have likely eased concerns over Chinese regulatory hurdles, strengthening investor confidence in the deal's viability'. CK Hutchison said it 'intends to allow such time as is required for such discussions to achieve' a workable arrangement. It said it had stated on several occasions that it 'will not proceed with any transaction that does not have the approval of all relevant authorities'. Its Hong Kong-listed shares climbed nearly one percent Monday, while Cosco rose 0.5 percent. The consortium's original structure was designed to pass control of CK Hutchison's two Panama ports to BlackRock's Global Infrastructure Partners unit, while the remaining ports will go to Italian billionaire Gianluigi Aponte's Terminal Investment Limited. AFP has contacted Cosco for comment. The Panama Ports Company, a CK Hutchison subsidiary, has managed the port of Cristobal on the canal's Atlantic side and Balboa on the Pacific side since 1997, via a concession from the Panama government.
